The EU could see its fifth COVID-19 vaccine approved in a matter of weeks after the European Medicines Agency said it had begun reviewing Novavax, Inc.’s application for a conditional marketing authorization (CMA) for Nuvaxovid (also known as NVX-CoV2373).
The EMA said the evaluation would be carried out under an accelerated timeline because it had already assessed a substantial proportion of the data during the rolling review stage, which...